Search

Your search keyword '"Perentes, Jean"' showing total 236 results
Start Over Author "Perentes, Jean" Search Limiters Full Text
236 results on '"Perentes, Jean"'

2. Phase I clinical trial testing the dose escalation and expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin administration (PITHAC) for the management of pleural carcinosis

Author

Chriqui, Louis-Emmanuel, Abdelnour-Berchtold, Etienne, Zanfrini, Edoardo, Devesa-Perez, Severine, Gonzalez, Michel, Krueger, Thorsten, Ellefsen, Kim, Destaillats, Alice, Bonnet, David, Hübner, Martin, Bouchaab, Hasna, Bassani-Sternberg, Michal, Peters, Solange, Cavin, Sabrina, and Perentes, Jean Y

Published
2024
Full Text
View/download PDF

4. Extended resection for potentially operable patients with stage III non–small cell lung cancer after induction treatment

Author

Furrer, Katarzyna, Weder, Walter, Eboulet, Eric Innocents, Betticher, Daniel, Pless, Miklos, Stupp, Roger, Krueger, Thorsten, Perentes, Jean Yannis, Schmid, Ralph A., Lardinois, Didier, Furrer, Markus, Früh, Martin, Peters, Solange, Curioni-Fontecedro, Alessandra, Stahel, Rolf A., Rothschild, Sacha I., Hayoz, Stefanie, and Opitz, Isabelle

Published
2022
Full Text
View/download PDF

5. Effectiveness of rib fixation compared to pain medication alone on pain control in patients with uncomplicated rib fractures: study protocol of a pragmatic multicenter randomized controlled trial—the PAROS study (Pain After Rib OSteosynthesis)

Author

Perentes, Jean Yaniss, Christodoulou, Michel, Abdelnour-Berchtold, Etienne, Karenovics, Wolfram, Gayet-Ageron, Angèle, Gonzalez, Michel, Krueger, Thorsten, Triponez, Frédéric, Terrier, Philippe, and Bédat, Benoît

Published
2022
Full Text
View/download PDF

7. Antiangiogenic immunotherapy suppresses desmoplastic and chemoresistant intestinal tumors in mice

Author

Ragusa, Simone, Prat-Luri, Borja, Gonzalez-Loyola, Alejandra, Nassiri, Sina, Squadrito, Mario Leonardo, Guichard, Alan, Cavin, Sabrina, Gjorevski, Nikolce, Barras, David, Marra, Giancarlo, Lutolf, Matthias P., Perentes, Jean, Corse, Emily, Bianchi, Roberta, Wetterwald, Laureline, Kim, Jaeryung, Oliver, Guillermo, Delorenzi, Mauro, De Palma, Michele, and Petrova, Tatiana V.

Subjects
Cancer -- Genetic aspects -- Drug therapy -- Prognosis -- Analysis -- Health aspects, Chemotherapy -- Analysis -- Health aspects, Vascular endothelial growth factor -- Analysis -- Health aspects, Colorectal cancer -- Genetic aspects -- Drug therapy -- Prognosis -- Analysis -- Health aspects, Immunotherapy -- Analysis -- Health aspects, Gastrointestinal diseases -- Genetic aspects -- Drug therapy -- Prognosis -- Analysis -- Health aspects, Antineoplastic agents -- Analysis -- Health aspects, T cells -- Analysis -- Health aspects, Cancer treatment, Endothelial growth factors, Tumors, Cancer cells, Endothelium, Antibodies, Fibrosis, Health care industry
Abstract

Mutations in APC promote colorectal cancer (CRC) progression through uncontrolled WNT signaling. Patients with desmoplastic CRC have a significantly worse prognosis and do not benefit from chemotherapy, but the mechanisms underlying the differential responses of APC-mutant CRCs to chemotherapy are not well understood. We report that expression of the transcription factor prospero homeobox 1 (PROX1) was reduced in desmoplastic APC-mutant human CRCs. In genetic Ape-mutant mouse models, loss of Prox1 promoted the growth of desmoplastic, angiogenic, and immunologically silent tumors through derepression of Mmp14. Although chemotherapy inhibited Prox1-proficient tumors, it promoted further stromal activation, angiogenesis, and invasion in Prox1-deficient tumors. Blockade of vascular endothelial growth factor A (VEGFA) and angiopoietin-2 (ANGPT2) combined with CD40 agonistic antibodies promoted antiangiogenic and immunostimulatory reprogramming of Prox1-deficient tumors, destroyed tumor fibrosis, and unleashed T cell-mediated killing of cancer cells. These results pinpoint the mechanistic basis of chemotherapy-induced hyperprogression and illustrate a therapeutic strategy for chemoresistant and desmoplastic CRCs., Introduction Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide (1). Patients with stage III or IV CRC have a high risk of recurrence and are [...]

Published
2020
Full Text
View/download PDF

12. Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)

Author

Curioni-Fontecedro, Alessandra, Perentes, Jean Yannis, Gelpke, Hans, Xyrafas, Alexandros, Bouchaab, Hasna, Mach, Nicolas, Matzinger, Oscar, Stojcheva, Nina, Frueh, Martin, Weder, Walter, Cathomas, Richard, Gargiulo, Piera, Bubendorf, Lukas, Pless, Miklos, Betticher, Daniel, Peters, Solange, and for the Swiss Group of Clinical Cancer Research (SAKK)

Published
2019
Full Text
View/download PDF

15. Abstract 6399: Hyperthermic intrathoracic chemotherapy (HITOC) improves malignant pleural mesothelioma control through a tumor specific cytotoxic immune response

Author

Hao, Yameng, primary, Gkasti, Aspasia, additional, Chriqui, Louis-Emmanuel, additional, Marie, Damien, additional, Gonzalez, Michel, additional, Krueger, Thorsten, additional, Peters, Solange, additional, Dyson, Paul J., additional, Meylan, Etienne, additional, Joyce, Johanna, additional, Cavin, Sabrina, additional, and Perentes, Jean Y., additional

Published
2023
Full Text
View/download PDF

16. Abstract 5152: Photodynamic therapy promotes immune infiltration and control of malignant pleural mesothelioma through NF-kB mediated upregulation of E-Selectin in the tumor vasculature

Author

Chriqui, Louis-Emmanuel, primary, Hao, Yameng, additional, Marie, Damien, additional, Gonzalez, Michel, additional, Krueger, Thorsten, additional, Meylan, Etienne, additional, Joyce, Johanna, additional, Cavin, Sabrina, additional, and Perentes, Jean-Yannis, additional

Published
2023
Full Text
View/download PDF

33. GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy

Author

Ancey, Pierre-Benoit, Contat, Caroline, Boivin, Gael, Sabatino, Silvia, Pascual, Justine, Zangger, Nadine, Perentes, Jean Yannis, Peters, Solange, Abel, Dale, Kirsch, David, Rathmell, Jeffrey, Vozenin, Marie-Catherine, Meylan, Etienne, Ancey, Pierre-Benoit, Contat, Caroline, Boivin, Gael, Sabatino, Silvia, Pascual, Justine, Zangger, Nadine, Perentes, Jean Yannis, Peters, Solange, Abel, Dale, Kirsch, David, Rathmell, Jeffrey, Vozenin, Marie-Catherine, and Meylan, Etienne

Abstract

info:eu-repo/semantics/published

Published
2021

34. Experimental ex vivo lung perfusion with sevoflurane: effects on damaged donor lung grafts

Author

Wang, Xingyu, Parapanov, Roumen, Francioli, Cyril, Perentes, Jean Yannis, Letovanec, Igor, Gonzalez, Michel, Kern, Christian, Ris, Hans-Beat, Piquilloud, Lise, Marcucci, Carlo, Krueger, Thorsten, Liaudet, Lucas, Gronchi, Fabrizio, Wang, Xingyu, Parapanov, Roumen, Francioli, Cyril, Perentes, Jean Yannis, Letovanec, Igor, Gonzalez, Michel, Kern, Christian, Ris, Hans-Beat, Piquilloud, Lise, Marcucci, Carlo, Krueger, Thorsten, Liaudet, Lucas, and Gronchi, Fabrizio

Abstract

OBJECTIVES Volatile anaesthetics can provide significant protection against reperfusion injury in various experimental settings. The aim of this study was to assess the potential of sevoflurane treatment, the most commonly used volatile anaesthetic in modern anaesthesia, in rat lungs donated after circulatory death and reconditioned in an ex vivo lung perfusion (EVLP) system. METHODS Fifteen rats were sacrificed and divided into 3 groups. In the control and sevoflurane groups, the heart-lung blocks were exposed to 1 h of warm ischaemia and 2 h of cold ischaemia and were mounted on an EVLP circuit for 3 h, in the absence or in the presence of 2% sevoflurane. In the baseline group, heart-lung blocks were harvested immediately after euthanasia. Physiological data, lung nitro-oxidative stress, lactate dehydrogenase (LDH), expression of cytokines, oedema and histopathological findings were assessed during or post-EVLP. RESULTS The sevoflurane group showed significantly reduced LDH (8.82 ± 3.58 arbitrary unit vs 3.80 ± 3.02 arbitrary unit, P = 0.03), protein carbonyl (1.17 ± 0.44 nmol⋅mg−1 vs 0.55 ± 0.11 nmol⋅mg−1, P = 0.006), 3-nitrotyrosine (197.44 ± 18.47 pg⋅mg−1 vs 151.05 ± 23.54 pg⋅mg−1, P = 0.004), cytokine-induced neutrophil chemoattractant factor 1 (1.17 ± 0.32 ng⋅mg−1 vs 0.66 ± 0.28 ng⋅mg−1, P = 0.03) and tumour necrosis factor alpha (1.50 ± 0.59 vs 0.59 ± 0.38 ng⋅mg−1, P = 0.02) when compared with the control group. In addition, sevoflurane lungs gained significantly less weight (0.72 ± 0.09 g vs 0.72 ± 0.09 g, P = 0.044), had less perivascular oedema (0.58 ± 0.09 vs 0.47 ± 0.07, P = 0.036), and improved static pulmonary compliance (+0.215 ml⋅cmH2O−1, P = 0.003) and peak airways pressure (-1.33 cmH2O, P = 0.04) but similar oxygenation capacity (+1.61 mmHg, P = 0.77) and pulmonary vascular resistances (+0.078 mmHg⋅min⋅ml−1, P = 0.15) when compared with the control group. CONCLUSIONS These findings suggest that the potential of sevoflurane in protecting t

Published
2021

36. GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy

Author

Ancey, Pierre-Benoit, primary, Contat, Caroline, additional, Boivin, Gael, additional, Sabatino, Silvia, additional, Pascual, Justine, additional, Zangger, Nadine, additional, Perentes, Jean Yannis, additional, Peters, Solange, additional, Abel, E. Dale, additional, Kirsch, David G., additional, Rathmell, Jeffrey C., additional, Vozenin, Marie-Catherine, additional, and Meylan, Etienne, additional

Published
2021
Full Text
View/download PDF

38. Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study

Author

Forster, Céline, primary, Doucet, Valérie, additional, Perentes, Jean Yannis, additional, Abdelnour-Berchtold, Etienne, additional, Zellweger, Matthieu, additional, Faouzi, Mohamed, additional, Bouchaab, Hasna, additional, Peters, Solange, additional, Marcucci, Carlo, additional, Krueger, Thorsten, additional, Rosner, Lorenzo, additional, and Gonzalez, Michel, additional

Published
2021
Full Text
View/download PDF

44. Low-dose photodynamic therapy promotes a cytotoxic immunological response in a murine model of pleural mesothelioma

Author

Cavin, Sabrina, Gkasti, Aspasia, Faget, Julien, Hao, Yameng, Letovanec, Igor, Reichenbach, Maxime, Gonzalez, Michel, Krueger, Thorsten, Dyson, Paul, Meylan, Etienne, Perentes, Jean Yannis, Cavin, Sabrina, Gkasti, Aspasia, Faget, Julien, Hao, Yameng, Letovanec, Igor, Reichenbach, Maxime, Gonzalez, Michel, Krueger, Thorsten, Dyson, Paul, Meylan, Etienne, and Perentes, Jean Yannis

Abstract

OBJECTIVES Malignant pleural mesothelioma (MPM) is a deadly disease with limited treatment options. Approaches to enhance patient immunity against MPM have been tested but shown variable results. Previously, we have demonstrated interesting vascular modulating properties of low-dose photodynamic therapy (L-PDT) on MPM. Here, we hypothesized that L-PDT vascular modulation could favour immune cell extravasation in MPM and improve tumour control in combination with immune checkpoint inhibitors. METHODS First, we assessed the impact of L-PDT on vascular endothelial E-selectin expression, a key molecule for immune cell extravasation, in vitro and in a syngeneic murine model of MPM. Second, we characterized the tumour immune cell infiltrate by 15-colour flow cytometry analysis 2 and 7 days after L-PDT treatment of the murine MPM model. Third, we determined how L-PDT combined with immune checkpoint inhibitor anti-CTLA4 affected tumour growth in a murine MPM model. RESULTS L-PDT significantly enhanced E-selectin expression by endothelial cells in vitro and in vivo. This correlated with increased CD8+ T cells and activated antigen-presenting cells (CD11b+ dendritic cells and macrophages) infiltration in MPM. Also, compared to anti-CTLA4 that only affects tumour growth, the combination of L-PDT with anti-CTLA4 caused complete MPM regression in 37.5% of animals. CONCLUSIONS L-PDT enhances E-selectin expression in the MPM endothelium, which favours immune infiltration of tumours. The combination of L-PDT with immune checkpoint inhibitor anti-CTLA4 allows best tumour control and regression., info:eu-repo/semantics/published

Published
2020

45. MOESM2 of Comparison of postoperative complications between segmentectomy and lobectomy by video-assisted thoracic surgery: a multicenter study

Author

Bédat, Benoît, Abdelnour-Berchtold, Etienne, Perneger, Thomas, Marc-Joseph Licker, Stefani, Alexandra, Krull, Matthieu, Perentes, Jean, Krueger, Thorsten, Triponez, Frédéric, Karenovics, Wolfram, and Gonzalez, Michel

Subjects
parasitic diseases, nutritional and metabolic diseases, human activities, tissues
Abstract

Additional file 2. Comparison of propensity score according to type of intervention by VATS VATS: Video-assisted thoracic surgery, SD: Standard deviation, AUC: Area under the curve, CI: Confidence interval.

Published
2019
Full Text
View/download PDF

46. Métastases pulmonaires : une maladie chirurgicale ?

Author

Dackam, Sandrine, Ojanguren, Amaia, Perentes, Jean Yannis, Abdelnour-Berchtold, Etienne, Krueger, Thorsten, Karenovics, Wolfram, Triponez, Frédéric, and Gonzalez, Michel

Subjects
Postoperative Complications, ddc:617, Metastasectomy, Quality of Life, Humans, Lung Neoplasms/secondary/surgery, Prospective Studies, Pneumonectomy, Retrospective Studies
Abstract

Au cours d'un cancer, 40 % des patients vont développer des métastases pulmonaires et dans cette situation un traitement seul de chimiothérapie est généralement peu efficace. Même s'il n'existe pas d'études randomisées prospectives qui confirment le bénéfice de la métastasectomie pulmonaire chirurgicale, diverses études ont montré l'existence d'un groupe de patients atteints de métastases pulmonaires qui bénéficient d'une résection à visée curative en cas de résection complète des métastases pulmonaires. Différentes approches chirurgicales peuvent être utilisées ayant pour but principal une résection complète et une épargne maximale du parenchyme pulmonaire. Les approches minimales invasives semblent offrir une meilleure qualité de vie et un résultat oncologique équivalent à l'approche par voie ouverte

Published
2019

48. Outcome after extracorporeal membrane oxygenation-bridged lung retransplants: a single-centre experience

Author

Abdelnour-Berchtold, Etienne, primary, Federici, Sara, additional, Wurlod, Daniel-Adrien, additional, Bellier, Jocelyn, additional, Zellweger, Matthieu, additional, Kirsch, Matthias, additional, Nicod, Laurent, additional, Marcucci, Carlo, additional, Baeriswyl, Moira, additional, Liaudet, Lucas, additional, Soccal, Paola M, additional, Gonzalez, Michel, additional, Perentes, Jean Yannis, additional, Ris, Hans-Beat, additional, Krueger, Thorsten, additional, and Aubert, John-David, additional

Published
2019
Full Text
View/download PDF

49. Limited Index of Clinical Suspicion and Underdiagnosis of Histopathologically Documented Invasive Mold Infections.

Author

Coquereaumont, Grégoire Caudron de, Couchepin, Jade, Perentes, Jean Y, Krueger, Thorsten, Lovis, Alban, Rotman, Samuel, and Lamoth, Frederic

Subjects
DIAGNOSTIC errors, DIAGNOSIS, SUSPICION, AUTOPSY, CANCER patients
Abstract

Invasive mold infections (IMIs) are difficult to diagnose. This analysis of histopathologically proven IMIs at our institution (2010–2019) showed that 11/41 (27%) of them were not suspected at the time of biopsy/autopsy (9/17, 53% among autopsies). The rate of missed diagnosis was particularly high (8/16, 50%) among nonhematologic cancer patients. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

50. Short‐term local control after VATS segmentectomy and lobectomy for solid NSCLC of less than 2 cm.

Author

Darras, Marc, Ojanguren, Amaya, Forster, Céline, Zellweger, Matthieu, Perentes, Jean Yannis, Krueger, Thorsten, and Gonzalez, Michel

Subjects
CANCER patients, CANCER relapse, COMBINED modality therapy, COMPARATIVE studies, LONGITUDINAL method, LUNG cancer, LUNG tumors, PATIENTS, PNEUMONECTOMY, SURGERY, TUMOR classification, COMORBIDITY, LUMPECTOMY, TREATMENT effectiveness, RETROSPECTIVE studies, DESCRIPTIVE statistics, VIDEO-assisted thoracic surgery, EVALUATION
Abstract

Introduction: VATS pulmonary segmentectomy is increasingly proposed as a parenchyma‐sparing resection for tumors smaller than 2 cm in diameter. The aim of this study was to compare short‐term oncological results and local control in solid non‐small cell lung cancers (NSCLCs) <2 cm surgically treated by intentional VATS segmentectomy or lobectomy. Methods: This study was a single center retrospective study of consecutive patients undergoing VATS lobectomy (VL) or segmentectomy (VS) for solid <2 cm NSCLC from January 2014 to October 2019. Results In total, 188 patients with a median age of 65 years (male/female: 99/89) underwent VS (n = 96) or VL (n = 92). Segmentectomies in the upper lobes were performed in 57% and as a single segment in 55% of cases. There was no statistically significant difference between VS and VL in terms of demographics, comorbidities, postoperative outcomes, dissected lymph node stations (2.89 ± 0.95 vs. 2.93 ± 1, P = 0.58), rate of pN1 (2.2% vs. 2.1%, P = 0.96) or pN2 upstaging (1.09% vs. 1.06%, P = 0.98). Adjuvant chemotherapy was given in 15% of patients in the VL and 11% in the VS group. During follow‐up (median: 23 months), no patients presented with local nodal recurrence or on the stapler line (VS group). Three patients on VL and two in VS groups presented with recurrence on the remnant operated lung. New primary pulmonary tumors were diagnosed in 3.3% and 6.3% of patients in the VL and VS groups, respectively. Conclusions: Despite the short follow‐up, our preliminary data shows that local control is comparable for VATS lobectomy and VATS segmentectomy for patients with NSCLC <2 cm. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results